Test Price
1,200 AED✅ Home Collection Available
Flecainide Therapeutic Drug Monitoring Test in UAE | 1200 AED | LC-MS/MS Quantitation
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139)
Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain; VIP Mobile Phlebotomy 8AM–11PM
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed Experts
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
Test Overview & Methodology
Flecainide Therapeutic Drug Monitoring (TDM) employs Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) for precise serum quantitation to guide arrhythmia management. This method offers mass-selective detection with zero cross-reactivity, delivering superior accuracy compared to conventional immunoassay techniques. Monitoring flecainide levels is essential to avoid toxicity and optimise dosing for patients with cardiac rhythm disorders, particularly atrial fibrillation and supraventricular tachycardia.
| Aspect | Our Flecainide LC-MS/MS | Standard Immunoassay |
|---|---|---|
| Precision | LC-MS/MS – mass‑selective, zero cross‑reactivity | Polyclonal antibody – potential interference |
| Methodology | Tandem Mass Spectrometry (TMS) | Enzymatic/Fluorescence immunoassay |
| Speed | Batch sample by 7th; report 2–3 weeks | Faster but lower accuracy |
| Compliance | ISO 9001:2015, DHA/MOHAP aligned | Basic quality, not ISO‑certified TDM |
Physician Insight & Safety Protocols
Dr. Ajay Singh (General Practitioner | DHA: 36234132)
"Flecainide TDM must be interpreted alongside ECG findings and clinical presentation due to the narrow therapeutic window. Toxicity can paradoxically provoke proarrhythmia, making it crucial to never self-adjust dosage. I strongly advise all patients to have their cardiologist review every TDM report before any medication changes. Routine monitoring at steady state provides the most reliable guide to safe and effective therapy."
Critical Advisory – Medication Safety
⚠ Do not discontinue or alter prescribed flecainide dosage without consulting your treating physician. Abrupt changes may precipitate dangerous arrhythmias.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria
- Acute myocardial infarction (within 3 months)
- Severe heart failure (NYHA III–IV)
- Known hypersensitivity to flecainide
- Brugada syndrome or Brugada‑type ECG pattern
Emergency Red Flags – Seek Immediate ER Care
- New‑onset severe dizziness or syncope
- Palpitations, chest pain, or rapid pulse
- Widened QRS > 50% from baseline
- Signs of proarrhythmia on ECG
Patient FAQ & Clinical Guidance
1. What is the Flecainide Test used for?
The Flecainide Test measures serum drug concentration to prevent toxicity and ensure therapeutic efficacy in cardiac arrhythmia patients. It guides dosing adjustments for atrial fibrillation, supraventricular tachycardia, and other rhythm disorders where flecainide is prescribed.
2. How should I prepare for sample collection?
Collect blood 1 hour before the next scheduled dose in a plain red-top tube, strictly avoiding SST gel barrier tubes. No fasting is required, but inform your phlebotomist about all medications you are taking.
3. What are the risks if my flecainide level is too high?
Elevated flecainide levels can cause proarrhythmia, widening of the QRS complex, dizziness, and fainting. Immediate medical attention is required if palpitations, syncope, or severe dizziness occur after dosing. Always seek emergency care for these symptoms.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Governance
All patient data processing adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
DNA Labs UAE maintains strict confidentiality, encrypted data transmission, and secure storage protocols across all laboratory information systems. DHA Facility License Number 1143 governs all diagnostic operations at our Dubai Healthcare City premises.
Clinical & Logistical Metadata
| Test Name | Flecainide Therapeutic Drug Monitoring (LC-MS/MS) |
| Price (AED) | 1,200 AED |
| Turnaround Time | 2–3 working days from sample receipt at laboratory |
| Sample Type / Matrix | Serum (plain red-top tube, no SST gel barrier) |
| Methodology Used | Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) |
| ICD-10-CM Code | Z51.81 (Encounter for therapeutic drug level monitoring) |
| LOINC Code | 3531-1 (Flecainide [Mass/Volume] in Serum or Plasma) |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians